How ESG became top priority for pharma
![](https://achema.media/wp-content/uploads/2022/10/karolina-grabowska-image-copy-1024x682.jpg)
The development of vaccines, treatments and tests has transformed attitudes to an industry not previously known for its approach to ESG. And with pressure from patients, customers and investors there’s a renewed impetus.